@npriedig
 Boston, MA
Joined September 2025
  • Tweets60
  • Following134
  • Followers33
Nolan Priedigkeit retweeted
Anirban Maitra@Aiims1742Sep 30
Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic #PancreaticCancer: a randomized phase 2b trial @DrMhidalgo @Perlmutter_CC nature.com/articles/s41591-0…

Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancrea...

Nature Medicine - In the randomized phase 2b VIRAGE trial, patients with treatment-naive metastatic pancreatic cancer received the hyaluronidase-expressing oncolytic adenovirus zabilugene...

nature.com
1
8
30
2,629
Nolan Priedigkeit retweeted
nature
@NatureOct 1
Nature research paper: GPCR antagonism via rewiring of receptor trafficking and degradation go.nature.com/4z7A5ug

GPCR antagonism via rewiring of receptor trafficking and degradation

Nature - A strategy for functional G-protein-coupled receptor (GPCR) antagonism through bispecific antibody-mediated endocytosis and lysosomal degradation is reported.

nature.com
3
32
2
149
38,102
Nolan Priedigkeit retweeted
Erica Mayer@elmayermdSep 30
Excited for publication of results of the evERA breast cancer trial, demonstrating the efficacy of the oral SERD combination of giredestrant and everolimus in advanced ER+ breast cancer. Wonderful news for breast cancer patients and clinicians!
NEJM
@NEJMSep 30
In ER-positive, HER2-negative advanced breast cancer, giredestrant, an ER degrader and full ER antagonist, plus everolimus led to longer progression-free survival than standard endocrine therapy–everolimus; safety was similar. Full phase 3 evERA Breast Cancer trial results: nej.md/47ryfbF
A graph from an Original Article published in the New England Journal of Medicine article titled "Giredestrant plus Everolimus in Advanced Breast Cancer." The graph shows progression-free survival among patients with ESR1-mutated tumors. The trial name, evERA Breast Cancer, is in parentheses after the title. The NEJM identity sits at the bottom.

ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Giredestrant plus Everolimus in Advanced Breast Cancer." The graph shows progression-free survival among patients with ESR1-mutated tumors. The trial name, evERA Breast Cancer, is in parentheses after the title. The NEJM identity sits at the bottom.

5
19
1
71
5,405
Nolan Priedigkeit retweeted
Shom Goel@shomgoelAug 12
Delighted to share our new paper, published today in @Nature , led by @AprilCWatt and @AntonioAhnNZ at the @PeterMacCC and The University of Melbourne @uommedia Paper: nature.com/articles/s41586-0…

Rb-driven transcription limits its tumour-suppressive effects in breast cancer

Nature - CDK4/6 inhibition redirects Rb chromatin occupancy to activate oestrogen-responsive genes, counteracting its own ability to maintain therapeutic cell-cycle arrest.

nature.com
2
19
2
73
9,522
Congratulations to Dr. Faina Nakhlis, Breast Surgery, on her recent promotion as Associate Professor of Surgery at Harvard Medical School. #HMS #surgery #breastsurgery @harvardmed
1
5
19
1,732
Nolan Priedigkeit retweeted
nature
@NatureJun 24
Nature research paper: Alternate RNA decoding results in stable and abundant proteins in mammals go.nature.com/4uNMqkB

Alternate RNA decoding results in stable and abundant proteins in mammals

Nature - Alternate RNA decoding, an understudied process, leads to peptide sequence modifications that can have substantial functional effects on protein stability, tissue-specific proteomes and...

nature.com
2
40
2
147
28,836
Nolan Priedigkeit retweeted
MLB
@MLBMay 8
Jacob Misiorowski threw 10 pitches in the 1st inning: 102.4 MPH 103.0 MPH 102.8 MPH 102.7 MPH 103.2 MPH 103.3 MPH 103.3 MPH 103.5 MPH 103.1 MPH 103.6 MPH
381
1,995
527
20,792
2,625,419
New @Nature study: >50% of lung cancer metastases are seeded by other metastases, not the primary tumor. This "seeding from seeding" reveals a complex evolutionary cascade that allows cancer to colonize the body. nature.com/articles/s41586-0…

Evolutionary characterization of lung cancer metastasis

Nature - DNA-sequencing data from primary tumours and paired metastases from participants in the TRACERx lung study and PEACE autopsy programme are used to analyse the metastatic diversity of...

nature.com
7
174
10
630
72,476
Nolan Priedigkeit retweeted
Dana-Farber News
@DanaFarberNewsApr 24
Congratulations to @DanaFarber’s Alan D’Andrea, MD, and @judygarber5 on their election to the American Academy of Arts and Sciences. ➡️ bit.ly/4tvhFBb
11
37
1,600
Nolan Priedigkeit retweeted
Cancer Discovery@CD_AACRApr 19
Now online: Spatial integration of protein and chromosomal states reveals early copy number changes and genotype-associated immune neighborhoods in serous ovarian cancer evolution doi.org/10.1158/2159-8290.CD…
1
2
1
4
772
Nolan Priedigkeit retweeted
nature
@NatureApr 17
Nature research paper: Prospective evaluation of genomics-guided off-label treatment go.nature.com/4dV9h9n

Prospective evaluation of genomics-guided off-label treatment

Nature - Evaluation by the Drug Rediscovery Protocol of off-label use of 37 approved cancer drugs on 1,610 patients showed modest activities overall, although subgroups of responders suggest that...

nature.com
1
10
30
8,566
Our BCCB group is at #AACR26! Led by Diana Garcia, and working with @DrDAbravanel and I, we present the multi-omics and evolutionary analysis of the MBCproject Session: PO.MCB08.05 When: Wed April 22 2026, 9 AM - 12 PM Poster 7265 doi.org/10.1158/1538-7445.AM… @DFCI_BreastOnc

Abstract 7265: MBCproject: multi-omic profiling of metastatic breast cancer evolution through...

Abstract. The Metastatic Breast Cancer project (MBCproject) is a patient-partnered research study that has collected clinical, genomic, and survey data through online enrollment. The cohort includes...

aacrjournals.org
1
3
1
5
562
Nolan Priedigkeit retweeted
Elvina Almuradova
@Dr_ElvinaAMar 24
Leptomeningeal disease may no longer be a “therapeutic dead end.” TBCRC049 (phase II): ▪️ OS: 10 months (vs ~4–5 historical) ▪️ LM response: 38% ▪️ Neuro improvement: 58% ➡️ Tucatinib + trastuzumab + capecitabine shows real clinical activity #bcsm #oncology #HER2 @NatureCancer @Larvol @OncoAlert @PTarantinoMD
1
10
1
35
2,468
Congratulations to Jose Pablo Leone, MD on his promotion to Associate Professor of Medicine at Harvard Medical School!
2
5
1
35
1,059
Join us On April 11! Dr. Faina Nakhlis will talk about what happens in the OR, including Axillary Lymph Node Dissection, Modified Radical Mastectomy and Delayed Reconstruction as Standards of Care for IBC. Register Here: redcap.link/IBCPatientFourm2…
4
1
7
837
Nolan Priedigkeit retweeted
TIME
@TIMEJan 29
TIME’s new cover: Artemis II is poised for the first lunar mission since 1972 time.com/7346146/artemis-ii-…
445
4,450
660
21,103
2,131,278
Nolan Priedigkeit retweeted
Sara Tolaney@stolaney1Jan 29
Huge congratulations to @Otto_DFCI and the Alliance team!!!! Wonderful to see PATINA in @NEJM !!!! @DFCI_BreastOnc
Paolo Tarantino
@PTarantinoMDJan 28
PATINA is now out in @nejm. Among pts with HR+/HER2+ MBC progression-free after chemo induction, adding palbociclib to 1L ET+HER2-blockade maintenance prolonged PFS from 29 mo to an astonishing 44 months (HR 0.75, p=0.02). Congrats @Otto_DFCI & coauthors! nejm.org/doi/full/10.1056/NE…
1
13
55
4,093
PATINA study in @nejm Establishes 'maintenance' therapy as the standard after induction for 1st line HER2+ MBC. Congrats to @Otto_DFCI @DFCI_BreastOnc for remarkable persistence and work. nejm.org/doi/full/10.1056/NE…

Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer | NEJM

Dual anti–human epidermal growth factor receptor 2 (HER2) therapy plus chemotherapy followed by maintenance treatment with HER2-targeted and endocrine therapies is standard first-line treatment for...

nejm.org
3
12
43
2,788
Nolan Priedigkeit retweeted
Sarah Yáñez-Richards
@SarahYanezRJan 25
It's snowing in New York
25
1,015
134
14,871
1,167,845
Nolan Priedigkeit retweeted
Carmine Valenza@ValenzaCarmineJan 16
In this multicenter cohort of pts with pN+ ER+ eBC who remained premenop after 5y of LHRHa, extended ET was associated with a clinically meaningful benefit Thanks to all the coauthors! @Harvard @HarvardChanSPH @harvardmed @IEOufficiale @LaStatale @DFCI_BreastOnc @DanaFarber
G Curigliano MD PhD@curijoeyJan 16
Extending ET with OFS in premenopausal patients with node-positive eBC after 5 years of LHRHa treatment is associated with a clinically meaningful reduction in both invasive and distant breast cancer recurrences. ascopubs.org/doi/10.1200/JCO… @IEOufficiale @LaStatale @myESMO @ASCO

Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone...

PURPOSETo evaluate the clinical benefit of extended endocrine therapy (eET) after 5 years of adjuvant treatment with luteinizing hormone-releasing hormone agonists (LHRHa) in premenopausal women with...

ascopubs.org
3
9
30
3,224
Load more